Aranzazu Villasante

Dr. Aranzazu Villasante

Institute for Bioengineering of Catalonia -IBEC, Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2009 in Nature
Verified
Journal Article
Closed access
PDF file
HLHan Li
Han Li
Manuel ColladoManuel Collado
Manuel Collado
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
KSKaterina Strati
Katerina Strati
SOSagrario Ortega
Sagrario Ortega
MSManuel Serrano
Manuel Serrano

23 April 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
BLBohao Liu
Bohao Liu
BLBenjamin Lee
Benjamin Lee
KNKoki Nakanishi
Koki Nakanishi
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
RWRebecca Williamson
Rebecca Williamson
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic

1 September 2008 in Journal of Experimental Medicine
Verified
Journal Article
Open access
VYVirginia G. de YébEnes
Virginia G. de YébEnes
LBLaura Belver
Laura Belver
DPDavid G. Pisano
David G. Pisano
SGSusana GonzálEz
Susana GonzálEz
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
ARAlmudena R. Ramiro
Almudena R. Ramiro
Activated B cells reshape their primary antibody repertoire after antigen encounter by two molecular mechanisms: somatic hypermutation (SHM) and class switch recombination (CSR). SHM and CSR are initiated by activation-induced cytidine deaminase (AID) through the deamination of cytosine residues on the immunoglobulin loci, which leads to the generation of DNA mutations or double-strand break intermediates. As a bystander effect, endogenous AID levels can also promote the generation of chromosome translocations, suggesting that the fine tuning of AID expression may be critical to restrict B cell lymphomagenesis. To determine whether microRNAs (miRNAs) play a role in the regulation of AID expression, we performed a functional screening of an miRNA library and identified miRNAs that regulate CSR. One such miRNA, miR-181b, impairs CSR when expressed in activated B cells, and results in the down-regulation of AID mRNA and protein levels. We found that the AID 3′ untranslated region contains multiple putative binding sequences for miR-181b and that these sequences can be directly targeted by miR-181b. Overall, our results provide evidence for a new regulatory mechanism that restricts AID activity and can therefore be relevant to prevent B cell malignant transformation.

1 December 2012 in Cell Stem Cell
Verified
Journal Article
Open access
HLHan Li
Han Li
Manuel ColladoManuel Collado
Manuel Collado
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
AMAnder Matheu
Ander Matheu
CLCian J. Lynch
Cian J. Lynch
MSManuel Serrano
Manuel Serrano
The mechanisms responsible for the transcriptional silencing of pluripotency genes in differentiated cells are poorly understood. We have observed that cells lacking the tumor suppressor p27 can be reprogrammed into induced pluripotent stem cells (iPSCs) in the absence of ectopic Sox2. Interestingly, cells and tissues from p27 null mice, including brain, lung, and retina, present an elevated basal expression of Sox2, suggesting that p27 contributes to the repression of Sox2. Furthermore, p27 null iPSCs fail to fully repress Sox2 upon differentiation. Mechanistically, we have found that upon differentiation p27 associates to the SRR2 enhancer of the Sox2 gene together with a p130-E2F4-SIN3A repressive complex. Finally, Sox2 haploinsufficiency genetically rescues some of the phenotypes characteristic of p27 null mice, including gigantism, pituitary hyperplasia, pituitary tumors, and retinal defects. Collectively, these results demonstrate an unprecedented connection between p27 and Sox2 relevant for reprogramming and cancer and for understanding human pathologies associated with p27 germline mutations.

1 July 2017 in Biomaterials
Verified
Journal Article
Closed access
XYXiaoning Yuan
Xiaoning Yuan
YWYiyong Wei
Yiyong Wei
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
JNJohnathan J.D. Ng
Johnathan J.D. Ng
DADerya E. Arkonac
Derya E. Arkonac
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic

6 February 2015 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
Introduction: Drug toxicity often goes undetected until clinical trials, which are the most costly and dangerous phase of drug development. Both the cultures of human cells and animal studies have ...